Baudax Bio

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory drug (NSAID) for the treatment of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative drug assets, including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent targeting these NMBs.